The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study
Abstract
Purpose: The aim of this study was to identify factors predicting initial and late resistance of GI stromal tumor (GIST) patients to imatinib and to document the dose-response relationship in the prognostic subgroups. This study is based on the European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group randomized trial comparing two doses of imatinib in advanced disease. Patients and Methods: Initial resistance was defined as progression within 3 months of randomization, and late resistance was defined as progression beyond 3 months. Investigated cofactors include imatinib dose, age, sex, performance status, original disease site, site and size of lesions at trial entry, and baseline hematologic and biologic parameters. Results: Initial resistance was recorded for 116 (12%) of 934 assessable patients and was independently predicted by the presence of lung and absence of liver metastases, low hemoglobin level, and high granulocyte count. Among 818 patients who were alive and progression free at 3 months, 347 subsequent progressions were recorded, and late resistance was independently predicted by high baseline granulocyte count, primary tumor outside of the stomach, large tumor size, and low initial imatinib dose. The impact of initial dose on late resistance was mainly significant in patients with a high baseline granulocyte count (> 5.10 9/L) and in patients with tumors of GI origin outside of the stomach and small intestine. Conclusion: Our study identifies patients for whom initial and/or long-term treatment needs to be improved and patients who require a high initial dose. Correlation of these results with immunohistochemistry and molecular parameters may further help to understand the biologic mechanisms of resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Self-citationEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Diagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationBiology of Gastrointestinal Stromal Tumors
Corless, C. L., Fletcher, J. A., & Heinrich, M. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.140 · Cited by 1,224
Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review
Miettinen, M., El-Rifai, W., H, L., & Lasota, J. (2002) · Human Pathology · doi:10.1053/hupa.2002.124123 · Cited by 663
Prognosis of Gastrointestinal Smooth-Muscle (Stromal) Tumors: Dependence on Anatomic Site
Emory, T. S., Sobin, L. H., Lukes, L., Lee, D. H., & O'Leary, T. J. (1999) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199901000-00009 · Cited by 625
Management of malignant gastrointestinal stromal tumours
Joensuu, H., Fletcher, C., Dimitrijevic, S., Silberman, S., Roberts, P., & Demetri, G. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00899-9 · Cited by 567
Debiec-Rychter, M., Cools, J., Dumez, H., Sciot, R., Stul, M., Mentens, N., Vranckx, H., Wasag, B., Prenen, H., Roesel, J., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.020 · Cited by 494
Self-citationVerweij, J., van Oosterom, A., Blay, J.-Y., Judson, I., Rodenhuis, S., van der Graaf, W., Radford, J., Le Cesne, A., Hogendoorn, P. C. W., di Paola, E. D., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00836-5 · Cited by 404
Self-citationJudson, I., Ma, P., Peng, B., Verweij, J., Racine, A., di Paola, E. D., van Glabbeke, M., Dimitrijevic, S., Scurr, M., Dumez, H., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0876-0 · Cited by 193
Self-citationO'Dwyer, M. E., Mauro, M. J., Blasdel, C., Farnsworth, M., Kurilik, G., Hsieh, Y., Mori, M., & Druker, B. J. (2003) · Blood · doi:10.1182/blood-2003-02-0371 · Cited by 119
Cortes, J. E., Talpaz, M., O'Brien, S. M., Giles, F. J., Rios, M. B., Shan, J., Faderl, S. H., Garcia‐Manero, G., Ferrajoli, A., Wierda, W., et al. (2003) · Cancer · doi:10.1002/cncr.11629 · Cited by 99
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Shan, J., Rios, M. B., Faderl, S. H., Verstovšek, S., Garcia‐Manero, G., Wierda, W. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1035-3 · Cited by 61
Human Red Blood Cells: Rheological Aspects, Uptake, and Release of Cytotoxic Drugs
Dumez, H., Reinhart, W. H., Guetens, G., & de Bruijn, E. A. (2004) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360490452031 · Cited by 34
Cited by
Blanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H. C., Baker, L. H., Maki, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4452 · Cited by 1,073
Blanke, C. D., Demetri, G. D., von Mehren, M., Heinrich, M. C., Eisenberg, B., Fletcher, J. A., Corless, C. L., Fletcher, C. D. M., Roberts, P. J., Heinz, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4403 · Cited by 996
Debiec-Rychter, M., Sciot, R., Le Cesne, A., Schlemmer, M., Hohenberger, P., van Oosterom, A. T., Blay, J.-Y., Leyvraz, S., Stul, M., Casali, P. G., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.030 · Cited by 892
Self-citationSunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Heinrich, M. C., Maki, R. G., Corless, C. L., Antonescu, C. R., Harlow, A., Griffith, D., Town, A., Mckinley, A., Ou, W.-B., Fletcher, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7461 · Cited by 797
Metadata
- Authors
- Van Glabbeke, M., Verweij, J., Casali, P. G., Le Cesne, A., Hohenberger, P., Ray-Coquard, I., Schlemmer, M., van Oosterom, A. T., Goldstein, D., Sciot, R., Hogendoorn, P. C. W., Brown, M., Bertulli, R., & Judson, I. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-20
- Volume
- 23
- Issue
- 24
- Pages
- 5795-5804
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2145131634
- Cited by
- 280
- References
- 16
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.